[go: up one dir, main page]

US20170232024A1 - Pharmaceutical compositions for demodex related blepharitis and eyelid crusting - Google Patents

Pharmaceutical compositions for demodex related blepharitis and eyelid crusting Download PDF

Info

Publication number
US20170232024A1
US20170232024A1 US15/501,420 US201415501420A US2017232024A1 US 20170232024 A1 US20170232024 A1 US 20170232024A1 US 201415501420 A US201415501420 A US 201415501420A US 2017232024 A1 US2017232024 A1 US 2017232024A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
weight
range
present
topical pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/501,420
Inventor
Tiang Hin Jerry TAN
Yong Ming POR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jerry Tan Eye Surgery Pte Ltd
Tarsus Pharmaceuticals Inc
Original Assignee
Tarsus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarsus Pharmaceuticals Inc filed Critical Tarsus Pharmaceuticals Inc
Assigned to JERRY TAN EYE SURGERY PTE LTD reassignment JERRY TAN EYE SURGERY PTE LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: POR, YONG MING, TAN, TIANG HIN JERRY
Assigned to TARSUS PHARMACEUTICALS, INC. reassignment TARSUS PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JERRY TAN EYE SURGERY PTE LTD
Publication of US20170232024A1 publication Critical patent/US20170232024A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • the present invention relates to the formulation of ectoparasiticidal and antibiotic compositions into topical pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eyelid crusting.
  • This invention also relates to a topical pharmaceutical composition suitable for the treatment of mammalian ectoparasites.
  • Blepharitis represents one of the most common anterior segment disorders encountered in ophthalmology. Blepharitis produces a red-rimmed appearance at the margins of the eyelids. It affects both the upper and lower eyelids. Blepharitis tends to recur and can become chronic.
  • Blepharitis is inflammation usually involving the part of the eyelid where the eyelashes grow.
  • the eyes can eventually become red, itchy and irritated, with dandruff-like crusts appearing on the eyelashes (also known as “crusting”). It may also result in loss of lashes.
  • blepharitis A number of causes for blepharitis exist, including bacterial infections, parasitic infestation, viral infection and autoimmune conditions. Infective causes including bacteria and parasites are likely to be the most common causes.
  • blepharitis There are two types of blepharitis, i.e. anterior and posterior blepharitis.
  • Anterior blepharitis is a condition where the outside front edge of the eyelids is inflamed, where the eyelashes are attached.
  • Posterior blepharitis is a condition where the moist inside part of the eyelid is affected.
  • blepharitis The traditional treatment for blepharitis consists of lid hygiene, and the application of a variety of “proprietary” cleansers. The goal is to control the disease and its underlying causes, maintain vision and to avoid secondary complications. However, many chronic cases persist. Demodex mites have been thought to be an etiologic factor in many cases of anterior blepharitis with lid margin debris. Demodex infestations are commonly treated with systemic and topical administration of parasiticides. For example, ocular demodex can be treated by performing a daily eyelid margin scrub with diluted shampoo alone or in combinations with a mercury oxide ointment, a metronidazole gel, or a pilocarpine gel applied to the base of the eye lashes. However, these treatments frequently fail to eradicate the demodex parasite and the infestation persists.
  • U.S. Pat. No. 8,128,968 teaches a composition containing about 0.6% to about 20% of tea tree oil to treat ocular demodex infestations and related conditions. Tea tree oil treatments, however, suffer from several disadvantages. Tea tree oil can easily lead to eye irritation and cause stinging sensations. Even a small amount will induce tearing, if it reaches the ocular surface.. Due to the reflex tearing, dilution occurs and efficacy is reduced. Owing to the possibility of severe irritation, some eye centres carry out clinic based treatments, where the tea tree oil is professionally applied by an eye doctor. Tea tree oil compositions for home applications are thinner, which has little or perhaps no effect on the demodex mite population.
  • U.S. Pat. No. 5,952,372 teaches the use of treating demodex with oral administration of ivermectin. More specifically, oral ivermectin in a regimen of 200 micrograms per kilogram body weight per dose for 2 or 3 consecutive doses are given to the patient, at least 3 and not more than 7 days apart. Oral tetracycline was also given to the patients through consistent intermediate stages. However, this is an expensive medication regimen and requires repeated dosing. In our experience, a single dose, as used in some centers, does not eliminate the demodex mites. This is likely due to the pharmacokinetic properties of the ivermectin being partitioned into the various body compartments, with low concentrations at the specific target site.
  • U.S. Pat. No. 5,952,372 teaches topical ivermetin compounded to a 2% concentration by weight in a cream, lotion, or gel carrier vehicle as a treatment for all clinical stages and signs of rosacea in affected persons.
  • this is only in relation to using a single active agent, ivermectin, for the treatment of a general dermatological condition such as rosacea, rather than specifically targeting blepharitis.
  • Demodex mites have also been found to be associated with various bacteria, including bacillus oleronius. It is therefore possible that other bacteria play a role in the pathogenic process. Demodex mites killed by tea tree oil or via oral administration of ivermectin usually disintegrate on the ocular surface and release a variety of associated organisms, which probably explains why, in our experience, a proportion of patients continue to suffer the usual symptoms of blepharitis, despite eradication of the demodex mites.
  • the aim of this invention is to overcome blepharitis, by eliminating demodex mites and/or other associated bacteria.
  • the demodex species are microscopic, obligate, elongated mites which belong to the family “Demodicidae” of the order Acari of the class Arachnida.
  • Demodex folliculorum and demodex brevis are found parasitizing on the human body surface.
  • Demodex folliculorum occupies the hair follicles and upper sebaceous glands, whilst demodex brevis exists principally in the depth of the sebaceous glands [source: “ A meta - analysis of association between acne vulgaris and Demodex infestation ” by Ya-e Zhao, Li Hu, Li-Ping Wu, Jun-xian Ma, J Zhejiang Univ Sci B. 2012 March; 13 (3):192-202].
  • This invention contains a parasiticidal agent such as ivermectin, and an antibiotic such as oxytetracycline, or any other tetracycline or macrolide antibiotic.
  • an antibiotic such as oxytetracycline, or any other tetracycline or macrolide antibiotic.
  • Other types of antibiotics are also suitable, such as fluoroquinolones and aminoglycosides.
  • Tetracycline antibiotics comprise a class of anti-microbials with applications in human and veterinary medicine, and are among the most heavily used antibiotics in the world. The purpose of antibiotics is to kill harmful bacteria, where possible, or to at least reduce their proliferation with bacteriostatic compounds.
  • the pharmaceutical composition according to the invention are suited for treating blepharitis and may be in liquid, pasty form, and more particularly in the form of creams, ointments, milks, pomades, powders, impregnated pads, syndets, towelettes, solutions, gels, sprays, foams, suspensions, lotions, sticks, shampoos, or washing bases.
  • the pharmaceutical composition according to the invention is in the form of an emulsion of the cream.
  • the compositions according to the invention are in the form of an emulsion.
  • Most simple emulsions are oil-in-water, which means that the oil droplets are suspended in a continuous water phase, whereas others are water-in-oil.
  • Emulsions can be classified as either oil-in-water (O/W) or water-in-oil (W/O) emulsions, depending on whether oil or water is the dispersed phase.
  • Milk, cream and sauces are some examples of oil-in-water emulsions. O/W emulsion is preferred in this embodiment, where oil molecules are dispersed in water.
  • Cream regardless if it is cold cream, emollient cream, day cream, night cream, medicated cream, etc, all have the same basic emulsion formulation. The effectiveness of the cream further depends on the emulsion type and pH, as well as the type of oils, fats, alcohols and esters used.
  • sorbitol is used as a humectant, so that the cream will not “dry out” when exposed to the atmosphere for prolonged periods of time. It also assists in maintaining phase stability, such as preventing separation of the aqueous and non-aqueous components.
  • the other Ingredients used in this embodiment of the invention are determined by referring to the Cosmetic Ingredient Review (“CIR”), or any other toxicological reports, where available, so as to ensure that these chosen ingredients are suitable for topical application and have lower risk of causing ocular irritation.
  • CIR Cosmetic Ingredient Review
  • the CIR was established in 1976 by the industry trade association (then the Cosmetic, Toiletry, and Fragrance Association, now the Personal Care Products Council, located in the United States of America), with the support of the U.S. Food and Drug Administration and the Consumer Federation of America. Although funded by the Council, CIR and the review process are independent from the Council and the cosmetics industry.
  • emulsifying wax is used.
  • emulsifying wax There are several varieties of emulsifying wax available. Some are synthetically produced and some are vegetable-derived.
  • This embodiment uses vegetable-based emulsifying wax NF (which means that it conforms to the specifications of the National Formulary, or “NF”), which is from naturally occurring fats and esters, derived from cetostearyl alcohol.
  • NF National Formulary
  • Emulsifying wax (NF) is also suitable for most skin types as allergic reactions and skin sensitivities have rarely been recorded, in relation to such waxes.
  • Emulsifying Wax NF concentrations of the Emulsifying Wax NF in the range of 1% -10% are found in typical use in skin cream.
  • the ocular irritation of Emulsifying Wax NF was also studied in rabbits (according to the Draize method).
  • the “Draize Test” is an acute toxicity test devised in 1944 by the Food and Drug Administration toxicologists John H. Draize and Jacob M. Spines.
  • the procedure involves applying 0.5 mL or 0.5 g of a test substance to the eye or skin of a restrained, conscious animal, and then leaving it for a set amount of time before rinsing it out and recording its effects.
  • the Draize Test has since become an endorsed method to evaluate the safety of materials meant for use in or around the eyes.
  • Ethylhexyl Stearate is safe for use and the undiluted test material was at most mildly irritating to rabbit skin.
  • an undiluted test material which had a mean maximum irritation index (MMII) of 0.67 was poorly tolerated, whereas a 10% aqueous solution (which had a MMII of 0.33) was relatively well tolerated.
  • this embodiment of the invention uses diluted tocopheryl acetate.
  • Disodium EDTA was classified as a non-irritant in a primary mucous membrane irritation test using rabbit eyes. EDTA of approximately 0.5% to 1% is not toxic when added to balanced salt solutions.
  • MI/MCI Methylisothiazolinone and Methylchloroisothiazlinone
  • aqueous dilutions of MI/MCI-886 with concentrations of 0.056% a.i. were non-irritating; 0.28% a.i. was slight to moderately irritating; 0.56% and 1.7% a.i. were moderately to severely irritating; and 2.8% and 5.6% a.i. were severely irritating (corrosive).
  • Propylene Glycol As this invention is to be used topically, good absorption is achieved by using Propylene Glycol as a solvent for the ivermectin. According to the Cosmetic Ingredients Report Panel Meeting on Jun. 28-29, 2010, the ocular irritation of Propylene Glycol was determined using groups of 6 males and female New. Zealand white albino rabbits. Undiluted Propylene. Glycol was found to be a slight eye irritant. In this embodiment, Propylene Glycol is therefore diluted by approximately 10 times, and is therefore non-irritating to the eye, as seen in the our experimental studies on the patients.
  • the selection of the ingredients depends very much on the final purpose and the desired consistency (for example, creamy, hard, soft, greasy, or dry) of the invention. Changing one ingredient may also require changes in many others, if the physical characteristics of the invention are to be maintained.
  • compositions comprise the following range (by weight):
  • an antibiotic such as oxytetracycline, and/or other tetracycline, macrolide, fluoroquinolone, or aminoglycoside antibiotic. (1 to 5%)
  • disodium EDTA (0.01% to 0.1%)
  • the pharmaceutical composition according to the preferred embodiment is in the emulsion of a cream.
  • the invention is in the form of an ointment.
  • a cream is a preparation of a medication for topical use that contains a water base. Essentially, it is a preparation of oil in water.
  • An ointment is a preparation of a medication for topical use that contains an oil base, which is essentially a preparation of water in oil.
  • composition according to the invention which is in the form of an ointment, which comprise the following range (by weight):
  • the pharmaceutical composition according to the invention is therefore formulated in a way that it does not cause eye irritation, even if a small amount reaches the ocular surface.
  • This invention therefore allows patients to apply such medication themselves, without having to go to a clinic. Patients may be able to continuously repeat the dosage over a period of time, so as to ensure a lower risk of recurrence of blepharitis.
  • the topical application of the cream or ointment allows the ivermectin and antibiotic to be applied directly to the affected area, thus overcoming the problem associated with oral application of ivermectin being partitioned into the various body compartments, consequently with low concentrations at the specific target site.
  • the direct topical application of the cream or ointment onto the affected area also minimises the risk of medication-related side effects felt in other parts of the body.
  • the cream or ointment is applied to the eyelids, in particular to eyelashes and the base of the eyelashes.
  • the cream or ointment may also be used to treat other conditions. It was mentioned in “A meta-analysis of association between acne vulgaris and Demodex infestation”, published in 2012, that there is evidence (including one meta-analysis) which suggests a connection between acne vulgaris and demodex. There is also other evidence which suggests a relationship between acne rosacea and demodex. For example, an earlier publication, Severe Demodex folliculorum-associated Oculocutaneous Rosacea In A Girl Successfully Treated With Ivermectin (JAMA Dermatol 2014 January; 150 (1):61-3) reported the case of a 12-year old girl who was successfully treated with oral ivermectin.
  • the cream or ointment is topically administered every night to the affected areas, for the treatment of blepharitis and/or acne, to obtain the appropriate and desired treatment outcome, by using a clean finger or cotton bud.
  • the invention is to be applied in a light and gentle rubbing action across the base of the eyelashes by first closing the eyes and applying to the upper eyelid eyelash bases/roots, and then looking upwards so that the invention can be applied to the lower eyelid eyelash bases/roots.
  • the invention is left on the affected area overnight.
  • the invention is then removed with normal cleansing water in the morning, for a month, so as to avoid early recurrences from new generations of mites which may emerge from unaffected eggs.
  • demodex mites were viewed at 100 times of magnification, and counted to determine the mite density per lash follicle.
  • the eyelids were first cleaned with hot compresses and a clean towel to remove all crusts and debris.
  • the cream or ointment was then applied directly onto the affected area, by using a clean finger or a cotton-tipped applicator.
  • the cream or ointment covered the entire eyelashes and roots.
  • the cream or ointment was left on the affected area for the entire night, and then washed away in the morning. This process was repeated on a nightly basis, for a month.
  • the patients were then re-assessed for the presence of demodex mites, and no demodex mites were found on the eyelash roots of any patients. Before the treatment, many patients experienced itching on the eyelid margins. These patients were free of any symptoms, at the 1-month follow up.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting.

Description

    TECHNICAL FIELD
  • The present invention relates to the formulation of ectoparasiticidal and antibiotic compositions into topical pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eyelid crusting. This invention also relates to a topical pharmaceutical composition suitable for the treatment of mammalian ectoparasites.
    • DESCRIPTION OF BACKGROUND AND/OR RELATED AND/OR PRIOR ART
  • Blepharitis represents one of the most common anterior segment disorders encountered in ophthalmology. Blepharitis produces a red-rimmed appearance at the margins of the eyelids. It affects both the upper and lower eyelids. Blepharitis tends to recur and can become chronic.
  • Blepharitis is inflammation usually involving the part of the eyelid where the eyelashes grow. The eyes can eventually become red, itchy and irritated, with dandruff-like crusts appearing on the eyelashes (also known as “crusting”). It may also result in loss of lashes.
  • Recent studies show that ophthalmologists and optometrists observe blepharitis in approximately 37% to 47% of their patients. Despite the prevalence of blepharitis in both presentation and contribution to ocular conditions, there is little data on how eye care practitioners treat the disease.
  • A number of causes for blepharitis exist, including bacterial infections, parasitic infestation, viral infection and autoimmune conditions. Infective causes including bacteria and parasites are likely to be the most common causes. There are two types of blepharitis, i.e. anterior and posterior blepharitis. Anterior blepharitis is a condition where the outside front edge of the eyelids is inflamed, where the eyelashes are attached. Posterior blepharitis is a condition where the moist inside part of the eyelid is affected.
  • The traditional treatment for blepharitis consists of lid hygiene, and the application of a variety of “proprietary” cleansers. The goal is to control the disease and its underlying causes, maintain vision and to avoid secondary complications. However, many chronic cases persist. Demodex mites have been thought to be an etiologic factor in many cases of anterior blepharitis with lid margin debris. Demodex infestations are commonly treated with systemic and topical administration of parasiticides. For example, ocular demodex can be treated by performing a daily eyelid margin scrub with diluted shampoo alone or in combinations with a mercury oxide ointment, a metronidazole gel, or a pilocarpine gel applied to the base of the eye lashes. However, these treatments frequently fail to eradicate the demodex parasite and the infestation persists.
  • U.S. Pat. No. 8,128,968 teaches a composition containing about 0.6% to about 20% of tea tree oil to treat ocular demodex infestations and related conditions. Tea tree oil treatments, however, suffer from several disadvantages. Tea tree oil can easily lead to eye irritation and cause stinging sensations. Even a small amount will induce tearing, if it reaches the ocular surface.. Due to the reflex tearing, dilution occurs and efficacy is reduced. Owing to the possibility of severe irritation, some eye centres carry out clinic based treatments, where the tea tree oil is professionally applied by an eye doctor. Tea tree oil compositions for home applications are thinner, which has little or perhaps no effect on the demodex mite population.
  • U.S. Pat. No. 5,952,372 teaches the use of treating demodex with oral administration of ivermectin. More specifically, oral ivermectin in a regimen of 200 micrograms per kilogram body weight per dose for 2 or 3 consecutive doses are given to the patient, at least 3 and not more than 7 days apart. Oral tetracycline was also given to the patients through consistent intermediate stages. However, this is an expensive medication regimen and requires repeated dosing. In our experience, a single dose, as used in some centers, does not eliminate the demodex mites. This is likely due to the pharmacokinetic properties of the ivermectin being partitioned into the various body compartments, with low concentrations at the specific target site.
  • Alternatively, U.S. Pat. No. 5,952,372 teaches topical ivermetin compounded to a 2% concentration by weight in a cream, lotion, or gel carrier vehicle as a treatment for all clinical stages and signs of rosacea in affected persons. However, this is only in relation to using a single active agent, ivermectin, for the treatment of a general dermatological condition such as rosacea, rather than specifically targeting blepharitis.
  • Demodex mites have also been found to be associated with various bacteria, including bacillus oleronius. It is therefore possible that other bacteria play a role in the pathogenic process. Demodex mites killed by tea tree oil or via oral administration of ivermectin usually disintegrate on the ocular surface and release a variety of associated organisms, which probably explains why, in our experience, a proportion of patients continue to suffer the usual symptoms of blepharitis, despite eradication of the demodex mites.
    • DETAILED DESCRIPTION
  • The aim of this invention is to overcome blepharitis, by eliminating demodex mites and/or other associated bacteria.
  • The demodex species are microscopic, obligate, elongated mites which belong to the family “Demodicidae” of the order Acari of the class Arachnida. Demodex folliculorum and demodex brevis are found parasitizing on the human body surface. Demodex folliculorum occupies the hair follicles and upper sebaceous glands, whilst demodex brevis exists principally in the depth of the sebaceous glands [source: “A meta-analysis of association between acne vulgaris and Demodex infestation” by Ya-e Zhao, Li Hu, Li-Ping Wu, Jun-xian Ma, J Zhejiang Univ Sci B. 2012 March; 13 (3):192-202].
  • This invention contains a parasiticidal agent such as ivermectin, and an antibiotic such as oxytetracycline, or any other tetracycline or macrolide antibiotic. Other types of antibiotics are also suitable, such as fluoroquinolones and aminoglycosides. Tetracycline antibiotics comprise a class of anti-microbials with applications in human and veterinary medicine, and are among the most heavily used antibiotics in the world. The purpose of antibiotics is to kill harmful bacteria, where possible, or to at least reduce their proliferation with bacteriostatic compounds.
  • The pharmaceutical composition according to the invention are suited for treating blepharitis and may be in liquid, pasty form, and more particularly in the form of creams, ointments, milks, pomades, powders, impregnated pads, syndets, towelettes, solutions, gels, sprays, foams, suspensions, lotions, sticks, shampoos, or washing bases.
  • In a preferred embodiment of this invention, the pharmaceutical composition according to the invention is in the form of an emulsion of the cream. In this embodiment, the compositions according to the invention are in the form of an emulsion. Most simple emulsions are oil-in-water, which means that the oil droplets are suspended in a continuous water phase, whereas others are water-in-oil. Emulsions can be classified as either oil-in-water (O/W) or water-in-oil (W/O) emulsions, depending on whether oil or water is the dispersed phase. Milk, cream and sauces are some examples of oil-in-water emulsions. O/W emulsion is preferred in this embodiment, where oil molecules are dispersed in water. Water therefore evaporates more readily from O/W emulsion. There are also more complicated emulsions that are used to enhance the delivery and stability of certain active ingredients. The choice of emulsification system is therefore highly dependent on the choice of ingredients comprised in the cream. Cream, regardless if it is cold cream, emollient cream, day cream, night cream, medicated cream, etc, all have the same basic emulsion formulation. The effectiveness of the cream further depends on the emulsion type and pH, as well as the type of oils, fats, alcohols and esters used.
  • In the above preferred embodiment of this invention, sorbitol is used as a humectant, so that the cream will not “dry out” when exposed to the atmosphere for prolonged periods of time. It also assists in maintaining phase stability, such as preventing separation of the aqueous and non-aqueous components.
  • The other Ingredients used in this embodiment of the invention are determined by referring to the Cosmetic Ingredient Review (“CIR”), or any other toxicological reports, where available, so as to ensure that these chosen ingredients are suitable for topical application and have lower risk of causing ocular irritation. The CIR was established in 1976 by the industry trade association (then the Cosmetic, Toiletry, and Fragrance Association, now the Personal Care Products Council, located in the United States of America), with the support of the U.S. Food and Drug Administration and the Consumer Federation of America. Although funded by the Council, CIR and the review process are independent from the Council and the cosmetics industry.
  • In this embodiment, emulsifying wax is used. There are several varieties of emulsifying wax available. Some are synthetically produced and some are vegetable-derived. This embodiment uses vegetable-based emulsifying wax NF (which means that it conforms to the specifications of the National Formulary, or “NF”), which is from naturally occurring fats and esters, derived from cetostearyl alcohol. Emulsifying wax (NF) is also suitable for most skin types as allergic reactions and skin sensitivities have rarely been recorded, in relation to such waxes.
  • According to the Final Report on the Safety Assessment of Fossil and Synthetic Waxes, International Journal of Toxicology (May/June 1983, 3: 43-99), concentrations of the Emulsifying Wax NF in the range of 1% -10% are found in typical use in skin cream. The ocular irritation of Emulsifying Wax NF was also studied in rabbits (according to the Draize method). The “Draize Test” is an acute toxicity test devised in 1944 by the Food and Drug Administration toxicologists John H. Draize and Jacob M. Spines. Initially used for testing cosmetics, the procedure involves applying 0.5 mL or 0.5 g of a test substance to the eye or skin of a restrained, conscious animal, and then leaving it for a set amount of time before rinsing it out and recording its effects. The Draize Test has since become an endorsed method to evaluate the safety of materials meant for use in or around the eyes.
  • According to the Amended Safety Assessment of Alkyl Esters as Used in Cosmetics, Cosmetics Ingredient Review (Apr. 12, 2013), Ethylhexyl Stearate is safe for use and the undiluted test material was at most mildly irritating to rabbit skin. In a 6-day cumulative skin irritation study, an undiluted test material (which had a mean maximum irritation index (MMII) of 0.67) was poorly tolerated, whereas a 10% aqueous solution (which had a MMII of 0.33) was relatively well tolerated. In human testing, a formulation containing 7.6% of Ethylhexyl Stearate was not an irritant or sensitizer (56 subjects), and not phototoxic (10 subjects), and not a photosensitizer (27 subjects), although some slight reactions were reported in the photosensitisation study. The undiluted test material did not provoke any significant injury in the rabbit's eyes (max Primary Irritation Index (PII) 4.67/100 at 1 h). The Report stated that the reproductive toxicity of 2-ethyl-1-hexanol was already addressed in a fetotoxicity study (performed on diethylhexyl adipate); it was suggested that the fetotoxicity reported for mice in that study was actually due to a zinc deficiency and that given the extent of 2-ethyl-1-hexanol absorption and the load that would be expected to enter the hepatic circulation, the potential for 2-ethyl-1-hexanol-induced reproductive toxicity was not thought to be an issue.
  • According to the report: Safety Assessment of Cyclomethicone, Cyclotetrasiloxane, Cyclopentasiloxane, Cyclohexasiloxane, and Cycloheptasiloxane, International Journal of Toxicology (30 (Supplement 3)), rats were exposed to up to 700 ppm (0.07%) of Cyclopentasiloxane via inhalational (environmental) exposure for 5 days per week, for 12 months and 24 months respectively, and no eye lesions were found.
  • In the Report: Safely Assessment of Tocopherols and Tocotrienols as Used in Cosmetics, Cosmetics Ingredient Review (Apr. 4, 2014), it was reported that tocopheryl acetate was not irritating to rabbit eyes in one study, but it produced weak to moderate conjunctival irritation in another study (European Chemicals Agency. 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyldecyl)-2H-benzopyran-6-yl acetate). Undiluted tocopheryl acetate was instilled into the conjunctival sac of 3 Vienna White rabbits, and the eyes were not rinsed. The eyes were scored at 1, 24, 28, and 72 h after instillation. Slight irritation was observed at 1-48 h, and the eyes were normal at 72 h. In a modified Draize Test, the same protocol was followed, and undiluted dl-α-tocopherol was instilled into the eyes of six rabbits; again, the eyes were not rinsed. Weak to moderate conjunctival irritation (i.e., redness) was observed, which subsided by day 7. No corneal changes were reported.
  • Although mild irritation is shown in the studies by the European Chemical Agency (while some others showed no irritation), this embodiment of the invention uses diluted tocopheryl acetate.
  • According to the Final Report on the Safety Assessment of EDTA (Ethylenediaminetetraacetic acid), calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA, International Journal of Toxicology, (21 (Supplement 2); 95-142, 2002), Disodium EDTA was classified as a non-irritant in a primary mucous membrane irritation test using rabbit eyes. EDTA of approximately 0.5% to 1% is not toxic when added to balanced salt solutions.
  • According to the Final Report on the Safety Assessment of Methylisothiazolinone and Methylchloroisothiazlinone, Journal of the American College of Toxicology (Volume 11, Number 1, 1992), Methylisothiazolinone and Methylchloroisothiazlinone (MI/MCI) were evaluated for ocular irritation in eight Draize or modified Draize tests using albino rabbits. MI/MCI-886 ranging in concentration from 1.1% to 14% active ingredient (a.i.) and MI/MCI-GC with a 1.5% a.i. concentration were corrosive when tested as supplied. However, aqueous dilutions of MI/MCI-886 with concentrations of 0.056% a.i. were non-irritating; 0.28% a.i. was slight to moderately irritating; 0.56% and 1.7% a.i. were moderately to severely irritating; and 2.8% and 5.6% a.i. were severely irritating (corrosive).
  • As this invention is to be used topically, good absorption is achieved by using Propylene Glycol as a solvent for the ivermectin. According to the Cosmetic Ingredients Report Panel Meeting on Jun. 28-29, 2010, the ocular irritation of Propylene Glycol was determined using groups of 6 males and female New. Zealand white albino rabbits. Undiluted Propylene. Glycol was found to be a slight eye irritant. In this embodiment, Propylene Glycol is therefore diluted by approximately 10 times, and is therefore non-irritating to the eye, as seen in the our experimental studies on the patients.
  • The selection of the ingredients depends very much on the final purpose and the desired consistency (for example, creamy, hard, soft, greasy, or dry) of the invention. Changing one ingredient may also require changes in many others, if the physical characteristics of the invention are to be maintained.
  • Based on the abovementioned reports and scientific researches, various ingredients were selected for this invention.
  • According to one embodiment of the invention, the compositions comprise the following range (by weight):
  • ivermectin (1 to 5%)
  • an antibiotic such as oxytetracycline, and/or other tetracycline, macrolide, fluoroquinolone, or aminoglycoside antibiotic. (1 to 5%)
  • water (45 to 65%)
  • emulsifying wax NF (Cetearyl Alcohol, Polysorbate 60, PEG-150 Stearate, and Steareth-20) (5% to 15%)
  • ethylhexyl stearate (5% to 15%)
  • cyclopentasiloxane (0.01% to 0.05%)
  • sorbitol (1 to 10%)
  • tocopheryl acetate (0.01% to 0.5%)
  • disodium EDTA (0.01% to 0.1%)
  • propylene glycol (3% to 10%)
  • methylchloroisothiazolinone and methylisothiazolinone (0.001% to 0.01%).
  • The pharmaceutical composition according to the preferred embodiment is in the emulsion of a cream. In another embodiment, the invention is in the form of an ointment. A cream is a preparation of a medication for topical use that contains a water base. Essentially, it is a preparation of oil in water. An ointment is a preparation of a medication for topical use that contains an oil base, which is essentially a preparation of water in oil.
  • In another embodiment, the pharmaceutical composition according to the invention which is in the form of an ointment, which comprise the following range (by weight):
  • ivermectin (1-5%)
  • tetracycline (1-5%)
  • sorbitan monooleate (span 80) (3-5%)
  • light mineral oil (10%-15%)
  • petrolatum (70%-80%)
  • Whether in the form of a cream or ointment, the pharmaceutical composition according to the invention is therefore formulated in a way that it does not cause eye irritation, even if a small amount reaches the ocular surface. This invention therefore allows patients to apply such medication themselves, without having to go to a clinic. Patients may be able to continuously repeat the dosage over a period of time, so as to ensure a lower risk of recurrence of blepharitis.
  • In this invention, the topical application of the cream or ointment allows the ivermectin and antibiotic to be applied directly to the affected area, thus overcoming the problem associated with oral application of ivermectin being partitioned into the various body compartments, consequently with low concentrations at the specific target site. The direct topical application of the cream or ointment onto the affected area also minimises the risk of medication-related side effects felt in other parts of the body.
  • The cream or ointment is applied to the eyelids, in particular to eyelashes and the base of the eyelashes.
  • The cream or ointment may also be used to treat other conditions. It was mentioned in “A meta-analysis of association between acne vulgaris and Demodex infestation”, published in 2012, that there is evidence (including one meta-analysis) which suggests a connection between acne vulgaris and demodex. There is also other evidence which suggests a relationship between acne rosacea and demodex. For example, an earlier publication, Severe Demodex folliculorum-associated Oculocutaneous Rosacea In A Girl Successfully Treated With Ivermectin (JAMA Dermatol 2014 January; 150 (1):61-3) reported the case of a 12-year old girl who was successfully treated with oral ivermectin. Other reports include Correlation Between Serum Reactivity To Demodex-associated Bacillus Oleronius Proteins, and Altered Sebum Levels and Demodex Populations in Erythematotelangiectatic Rosacea Patients (J Med Microbiol 2014 February; 63 (Pt 2): 258-72, Evaluation of Demodex Folliculorum As A Risk Factor for the Diagnosis of Rosacea in Skin Biopsies (Indian J Dermatol. 2013 March, 58 (2):157, Potential Role of Demodex Mites and Bacteria in the Induction of Rosacea (J Med Microbiol 2012 November; 61 (Pt 11): 1504-10), and Correlation Between Ocular Demodex Infestation and Serum Immunoreactivity to Bacillus Proteins in Patients with Facial Rosacea (Ophthalmology 2010 May: 117 (5): 870-977). Accordingly, this invention may be used to treat other medical conditions as well.
  • The cream or ointment is topically administered every night to the affected areas, for the treatment of blepharitis and/or acne, to obtain the appropriate and desired treatment outcome, by using a clean finger or cotton bud. For example, the invention is to be applied in a light and gentle rubbing action across the base of the eyelashes by first closing the eyes and applying to the upper eyelid eyelash bases/roots, and then looking upwards so that the invention can be applied to the lower eyelid eyelash bases/roots. The invention is left on the affected area overnight.
  • The invention is then removed with normal cleansing water in the morning, for a month, so as to avoid early recurrences from new generations of mites which may emerge from unaffected eggs.
    • EXAMPLES
  • The following examples are merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. These examples are illustrative of the effectiveness of the invention.
  • Several patients had itching in the eyes and crusting around the eyelids. The presence of demodex mites was then confirmed. The confirmation was done by gently pulling on the eyelashes, and then transferring the presenting demodex mites onto a piece of cellophane tape. The said cellophane tape was then affixed onto a microscope slide. These demodex mites were viewed at 100 times of magnification, and counted to determine the mite density per lash follicle.
  • In treating the affected patients, the eyelids were first cleaned with hot compresses and a clean towel to remove all crusts and debris. The cream or ointment was then applied directly onto the affected area, by using a clean finger or a cotton-tipped applicator. The cream or ointment covered the entire eyelashes and roots.
  • The cream or ointment was left on the affected area for the entire night, and then washed away in the morning. This process was repeated on a nightly basis, for a month. The patients were then re-assessed for the presence of demodex mites, and no demodex mites were found on the eyelash roots of any patients. Before the treatment, many patients experienced itching on the eyelid margins. These patients were free of any symptoms, at the 1-month follow up.
  • Some cases were treated solely with ivermectin. However, these studies also demonstrate the necessity of antibiotics, in some cases.
    • Example 1
  • This 52 year old Chinese gentleman had a long history of facial skin rashes that occurred along the nasolabial fold (also commonly known as “smile lines” or “laugh lines”) as well as around the ears. He had previously been treated by dermatologists for a diagnosis of seborrhoeic dermatitis with various creams including topical steroids. He presented with increasing crusting around the eyelashes and intermittent eye irritation. On examination, erythematous macules and papules were noted along the glabellar area as well as the nasolabial folds bilaterally. Marked crusting and many demodex mites were found in the eyelash follicles. A sample retrieved from one eyelash revealed 5 demodex folliculorum in the single follicle. He was treated with Ivermectin (only comprising 1%) cream nightly to the eyelid margins (as prescribed), as well as the inflamed areas of his face. One month later the eyelid margin crusting had resolved, as had the facial rash. No demodex mites were found in the eyelash follicles after the treatment.
    • Example 2
  • This 44 year old Caucasian gentleman had recurring redness of the eyes associated with itching and burning sensations for the past 6 years. On examination, eyelash crusting together with lid margin erythema and many demodex mites were seen. He was first treated with oral Ivermectin (Stromectol) 12 mg and was advised to do scrubs using Tea Tree Oil on the eyelids twice a day. Over the next 2 months, the demodex mites reduced in numbers but were not completely eliminated, despite 4 subsequent doses of oral Ivermectin and continuing Tea Tree Oil scrubs. Tea Tree Oil applications were also performed on the patient. Owing to the persistence of the mites, dosages of Ivermectin (1%) cream was prescribed instead. After nightly applications of this cream for one month (as prescribed), no demodex mites were seen in the eyelash follicles and his ocular inflammation had markedly improved.
    • Example 3
  • This 28 year old Chinese gentleman had recurring redness on the left eyelids for the past 9 years and had been treated previously with a variety of topical antibiotics including Framycetin. On examination, he had asymmetric disease, with severe inflammation of the left eyelid margins and corneal punctate erosions. Some demodex mites were seen in the eyelash follicles. He was treated with a combination of Ivermectin (1%) cream as well as Tetracycline eye ointment to the eyelids. Oral Doxycycline 100 mg twice a day was prescribed. Demodex mites resident in the lash follicles were eradicated after 1 month of nightly Ivermectin cream applications, as prescribed. Although eyelid inflammation was reduced, it was not entirely eliminated and the topical and oral tetracycline treatment was continued for the next 2 months. 4 months after initial presentation, the eyelids were much improved and inflammation had subsided. He was followed up for 2 years, and during this time remained free of severe episodes of eye or eyelid inflammation. A mild recurrence of demodex infestation was noted at the second year mark, and this was treated successfully with a further course of Ivermectin (1%) cream.

Claims (48)

What is claimed is:
1. A method for the treatment of eyelid inflammation, in particular demodex related blepharitis and eyelid crusting, comprising topically administering every night for a month onto the affected area of an individual in need of such treatment and removed with normal cleansing water in the morning, a topical pharmaceutical composition which comprises an effective amount of ivermectin and an antibiotic, said topical pharmaceutical composition being formulated as an emulsion of a cream, the topical pharmaceutical cream comprising:
water;
an humectant comprising sorbitol;
a mixture of emollient comprising cyclopentasiloxane, ethylhexyl stearate;
an emulsifier comprising emulsifying wax NF;
a mixture of preservatives comprising methylchloroisothiazolinone, disodium EDTA;
an antioxidant comprising tocopheryl acetate; and
a solvent comprising propylene glycol.
2. The method defined by claim 1, wherein said ivermectin is present in the range of 1 to 5% (by weight) of the topical pharmaceutical composition.
3. The method defined by claim 1, wherein said antibiotic comprises of oxytetracycline in the range of 1% to 5% (by weight) of the topical pharmaceutical composition.
4. The method defined by claim 1, wherein said water is present in the range of 45% to 65% (by weight) of the topical pharmaceutical composition.
5. The method defined by claim 1, wherein said sorbitol is present in the range of 1% to 10% (by weight) of the topical pharmaceutical composition.
6. The method defined by claim 1, wherein said cyclopentasiloxane is present in the range of 0.01% to 0.05% (by weight) of the topical pharmaceutical composition.
7. The method defined by claim 1, wherein said ethylhexyl stearate is present in the range of 5% to 15% (by weight) of the topical pharmaceutical composition.
8. The method defined by claim 1, wherein said emulsifying wax NF is present in the range of 5% to 15% (by weight) of the topical pharmaceutical composition.
9. The method defined by claim 1, wherein said methylchloroisothiazolinone is present in the range of 0.001% to 0.01% (by weight) of the topical pharmaceutical composition.
10. The method defined by claim 1, wherein said disodium EDTA is present in the range of 0.01% to 0.1% (by weight) of the topical pharmaceutical composition.
11. The method defined by claim 1, wherein said tocopheryl acetate is present in the range of 0.01% to 0.5% (by weight) of the topical pharmaceutical composition.
12. The method defined by claim 1, wherein said propylene glycol is present in the range of 3% to 10% (by weight) of the topical pharmaceutical composition.
13. The method defined by claim 1 and claim 3, wherein said antibiotic can also comprise tetracycline.
14. The method defined by claim 1 and claim 3, wherein said antibiotic can also comprise a macrolide antibiotic.
15. The method defined by claim 1 and claim 3, wherein said antibiotic can also comprise fluoroquinolones.
16. The method defined by claim 1 and claim 3, wherein said antibiotic can also comprise aminoglycosides.
17. A method for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting, comprising topically administering every night for a month onto the affected area of an individual in need of such treatment and removed with normal cleansing water in the morning, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin and an antibiotic comprising either tetracycline, macrolide, fluoroquinolone, or aminoglycoside, said topical pharmaceutical composition being formulated as an ointment, the topical pharmaceutical ointment comprising:
a solvent comprising sorbitan monooleate (span 80);
a mixture of ointment base comprising light mineral oil, petrolatum.
18. The method defined by claim 17 wherein said ivermectin is present in the range of 1% to 5% (by weight) of the topical pharmaceutical composition.
19. The method defined by claim 17 wherein said tetracycline is present in the range of 1% to 5% (by weight) of the topical pharmaceutical composition.
20. The method defined by claim 17 wherein said sorbitan monooleate is present in the range of 3% to 5% (by weight) of the topical pharmaceutical composition.
21. The method defined by claim 17 wherein said light mineral oil is present in the range of 10% to 15% (by weight) of the topical pharmaceutical composition.
22. The method defined by claim 17 wherein said petrolatum is present in the range of 70% to 80% (by weight) of the topical pharmaceutical composition.
23. A topically applicable stable pharmaceutical emulsion of cream, comprising:
ivermectin
an antibiotic;
water;
an humectant comprising sorbitol;
a mixture of emollient comprising cyclopentasiloxane, ethylhexyl stearate, an emulsifier comprising emulsifying wax NF;
a mixture of preservatives comprising methylchloroisothiazolinone, disodium EDTA;
an antioxidant comprising tocopheryl acetate; and
a solvent comprising propylene glycol.
24. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said ivermectin is present in the range of 1% to 5% (by weight) of the topical pharmaceutical composition.
25. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said antibiotic is present in the range of 1% to 5% (by weight) of the topical pharmaceutical composition.
26. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said water is present in the range of 45% to 65% (by weight) of the topical pharmaceutical composition.
27. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said sorbitol is present in the range of 1% to 10% (by weight) of the topical pharmaceutical composition.
28. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said cyclopentasiloxane is present in the range of 0.01% to 0.05% (by weight) of the topical pharmaceutical composition.
29. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said ethylhexyl stearate is present in the range of 5% to 15% (by weight) of the topical pharmaceutical composition.
30. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said emulsifying wax NF is present in the range of 5% to 15% (by weight) of the topical pharmaceutical composition.
31. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said methylchloroisothiazolinone is present in the range of 0.001% to 0.01% (by weight) of the topical pharmaceutical composition.
32. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said disodium EDTA is present in the range of 0.01% to 0.1% (by weight) of the topical pharmaceutical composition.
33. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said tocopheryl acetate is present in the range of 0.01% to 0.5% (by weight) of the topical pharmaceutical composition.
34. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23, wherein said propylene glycol is present in the range of 3% to 10% (by weight) of the topical pharmaceutical composition.
35. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23 and claim 25, wherein said antibiotic can also comprise tetracycline.
36. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23 and claim 25, wherein said antibiotic can also comprise macrolide antibiotic.
37. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23 and claim 25, wherein said antibiotic can also comprise fluoroquinolones.
38. The topically applicable stable pharmaceutical emulsion of cream as defined by claim 23 and claim 25, wherein said antibiotic can also comprise aminoglycosides.
39. A topically applicable stable pharmaceutical in the form of an ointment, comprising:
ivermectin;
an antibiotic;
a solvent comprising sorbitan monooleate (span 80); and
a mixture of ointment base comprising light mineral oil, petrolatum.
40. The topically applicable stable pharmaceutical in the form of an ointment as defined by claim 39 wherein said ivermectin is present in the range of 1% to 5% (by weight) of the topical pharmaceutical composition.
41. The topically applicable stable pharmaceutical in the form of an ointment as defined by claim 39 wherein said antibiotic is present in the range of 1% to 5% (by weight) of the topical pharmaceutical composition.
42. The topically applicable stable pharmaceutical in the form of an ointment as defined by claim 39 wherein said sorbitan monooleate is present in the range of 3% to 5% (by weight) of the topical pharmaceutical composition.
43. The topically applicable stable pharmaceutical in the form of an ointment as defined by claim 39 wherein said light mineral oil is present in the range of 10% to 15% (by weight) of the topical pharmaceutical composition.
44. The topically applicable stable pharmaceutical in the form of an ointment as defined by claim 39 wherein said petrolatum is present in the range of 70% to 80% (by weight) of the topical pharmaceutical composition.
45. The topically applicable stable pharmaceutical in the form of an ointment as defined by claim 39 and claim 41, wherein said antibiotic can also comprise tetracycline.
46. The topically applicable stable pharmaceutical in the form of an ointment as defined by claims 39 and 41, wherein said antibiotic can also comprise macrolide antibiotic.
47. The topically applicable stable pharmaceutical in the form of an ointment as defined by claim 39 and claim 41, wherein said antibiotic can also comprise fluoroquinolones.
48. The topically applicable stable pharmaceutical in the form of an ointment as defined by claim 39 and claim 41, wherein said antibiotic can also comprise aminoglycosides.
US15/501,420 2014-08-04 2014-08-04 Pharmaceutical compositions for demodex related blepharitis and eyelid crusting Abandoned US20170232024A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG2014/000371 WO2016022066A1 (en) 2014-08-04 2014-08-04 Pharmaceutical compositions for demodex related blepharitis and eyelid crusting

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2014/000371 A-371-Of-International WO2016022066A1 (en) 2014-08-04 2014-08-04 Pharmaceutical compositions for demodex related blepharitis and eyelid crusting

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/725,761 Continuation US20200338105A1 (en) 2014-08-04 2019-12-23 Pharmaceutical compositions for demodex related blepharitis and eyelid crusting

Publications (1)

Publication Number Publication Date
US20170232024A1 true US20170232024A1 (en) 2017-08-17

Family

ID=51355602

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/501,420 Abandoned US20170232024A1 (en) 2014-08-04 2014-08-04 Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US16/725,761 Abandoned US20200338105A1 (en) 2014-08-04 2019-12-23 Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US17/570,745 Active 2034-08-19 US12257263B2 (en) 2014-08-04 2022-01-07 Pharmaceutical compositions for demodex related blepharitis and eyelid crusting

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/725,761 Abandoned US20200338105A1 (en) 2014-08-04 2019-12-23 Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US17/570,745 Active 2034-08-19 US12257263B2 (en) 2014-08-04 2022-01-07 Pharmaceutical compositions for demodex related blepharitis and eyelid crusting

Country Status (2)

Country Link
US (3) US20170232024A1 (en)
WO (1) WO2016022066A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835517B2 (en) 2017-12-15 2020-11-17 Tarsus Pharmaceuticals, Inc. Methods for treating ocular demodex using isoxazoline parasiticide formulations
WO2021033154A1 (en) * 2019-08-20 2021-02-25 Padmanabhan Vishwanath Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
CN112770742A (en) * 2018-07-27 2021-05-07 阿佩塔生物科学有限公司 Spinosad formulations for the treatment of demodex-induced eye and face diseases
CN113242747A (en) * 2018-10-12 2021-08-10 好利安科技有限公司 Macrolide formulations, method for preparing them and use of said formulations in the treatment of diseases secondary to ocular parasites
US12257263B2 (en) 2014-08-04 2025-03-25 Tarsus Pharmaceuticals, Inc. Pharmaceutical compositions for demodex related blepharitis and eyelid crusting

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
EP3326609A1 (en) * 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without gelling agents
EP3326614A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
CN114269324A (en) * 2019-06-19 2022-04-01 塔苏斯制药有限公司 Isoxazoline anthelmintic formulations and methods for treating blepharitis
AU2021381495A1 (en) 2020-11-23 2023-06-22 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059382A1 (en) * 2001-04-12 2003-03-27 Brandt Loralei Marie Cosmetic compositions containing dispersion polymers
US20080039519A1 (en) * 2004-11-09 2008-02-14 Bayer Healthcare Ag Anti-Demodicosis Agent
US20110059925A1 (en) * 2008-03-26 2011-03-10 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781355A (en) 1969-12-12 1973-12-25 Boots Pure Drug Co Ltd Pesticidal compounds and compositions
US3864497A (en) 1970-12-01 1975-02-04 Boots Pure Drug Co Ltd Acaricidal and insecticidal 1,5-diphenyl-3-methyl-1,3,5-triazapenta-1,4-diener
US4389397A (en) 1980-08-04 1983-06-21 Merck & Co., Inc. Solubilization of ivermectin in water
US5019392A (en) 1988-03-03 1991-05-28 Micro-Pak, Inc. Encapsulation of parasiticides
US4957918A (en) 1988-06-09 1990-09-18 Leonard Bloom Topical treatment of blepharitis
US5614545A (en) * 1988-06-09 1997-03-25 Leonard Bloom Topical composition for treatment of blepharitis
US6001822A (en) 1989-04-11 1999-12-14 Pfizer Inc. Antiparasitic formulations
FR2656526B1 (en) 1990-01-02 1994-10-28 Virbac Sa Laboratoires CONTROLLED RELEASE DEVICE AND PREPARATION METHOD.
WO1994015597A1 (en) 1993-01-11 1994-07-21 Allergan, Inc. Ophthalmic compositions comprising benzyllauryldimethylammonium chloride
US5632999A (en) 1993-08-18 1997-05-27 Virbac, Inc. Sustained release pyriproxifen compositions for parasite control
US5981500A (en) 1994-01-12 1999-11-09 Pfizer Inc. Antiparasitic agents related to the milbemycins and avermectins
FR2729539B1 (en) 1995-01-23 1997-04-11 Virbac Lab DEVICE FOR CONTROLLED RELEASE OF CHEMICAL SUBSTANCES, FOR FIXING ON AN ANIMAL AND METHOD FOR PREPARING SAID DEVICE
DE19613972A1 (en) 1996-04-09 1997-10-16 Bayer Ag Injection formulations of avermectins and milbemycins based on castor oil
RU2126668C1 (en) 1996-10-17 1999-02-27 Багров Сергей Николаевич Ointment demalon for treatment of patients with blepharitis
FR2761886B1 (en) 1997-04-14 2000-05-05 Virbac Sa COMPOSITIONS CONTAINING AT LEAST ONE CATIONIC POLYMER AND AT LEAST ONE ACTIVE MOLECULE CONTAINED IN AT LEAST ONE MICRO OR NANOPARTICLE VECTOR AND THEIR USE FOR THE TREATMENT OF LIVE OR INERT SURFACES
US5968990A (en) 1997-10-14 1999-10-19 Isp Investments Inc. Water-dilutable, microemulsion concentrate and pour-on formulations thereof
ATE248773T1 (en) 1997-10-14 2003-09-15 Isp Investments Inc STABILIZED CONCENTRATES OF WATER UNSTABLE AZA COMPOUNDS AND WATER/OIL MINI EMULSIONS THEREOF
EP1075265B1 (en) 1998-05-08 2006-03-08 The University Of Miami Use of tetracyclines for treating meibomian gland disease
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
GB9825402D0 (en) 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
US7897559B2 (en) * 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7064108B2 (en) 2002-02-08 2006-06-20 Merck & Co., Inc. Topical ivermectin composition
US7906128B2 (en) 2002-10-21 2011-03-15 Wyeth Llc Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
PL378932A1 (en) * 2003-04-24 2006-06-12 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
FR2854074B1 (en) 2003-04-24 2007-11-23 Galderma Res & Dev USE OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
US7531186B2 (en) 2003-12-17 2009-05-12 Merial Limited Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz
KR101197482B1 (en) 2004-03-05 2012-11-09 닛산 가가쿠 고교 가부시키 가이샤 Isoxazoline-Substituted Benzamide Compound And Noxious Organism Control Agent
US8568794B2 (en) 2004-03-12 2013-10-29 Life Science Investments, Ltd. Topical and intravaginal microbicidal and antiparasitic compositions comprising quassinoids or quassinoid-containing plant extracts
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
PE20060785A1 (en) 2004-10-08 2006-09-19 Wyeth Corp AMITRAZ COMPOSITIONS
EP1807087A2 (en) 2004-10-12 2007-07-18 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
GB2419093A (en) 2004-10-12 2006-04-19 Ernir Snorrason Acetylcholinesterase inhibitors for the treatment of skin
DK1809238T3 (en) 2004-11-09 2010-01-25 Novagali Pharma Sa Ophthalmic emulsions containing an immunosuppressant
WO2006119174A1 (en) 2005-04-30 2006-11-09 Ocular Surface Center, P.A. Method for treating ocular demodex
FR2886851B1 (en) * 2005-06-10 2007-10-05 Galderma Sa COMPOSITION BASED ON AVERMECTIN AND METRONIDAZOLE, IN PARTICULAR FOR THE TREATMENT OF ROSACEA
FR2891460B1 (en) 2005-09-30 2010-07-30 Galderma Sa USE OF AT LEAST ONE COMPOUND OF THE AVERMECTIN FAMILY FOR THE TREATMENT OF OPHTHALMIC DISEASES DUE TO DEMODEX FOLLICULORUM.
TWI412322B (en) 2005-12-30 2013-10-21 Du Pont Isoxazolines for controlling invertebrate pests
FR2900052B1 (en) 2006-04-19 2011-02-18 Galderma Sa COMPOSITION COMPRISING AT LEAST ONE AQUEOUS PHASE AND AT LEAST ONE FATTY PHASE COMPRISING IVERMECTIN
DE602008005436D1 (en) 2007-05-09 2011-04-21 Ganial Immunotherapeutics Inc (S, R) -3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLEIC ACID STAIN OXIDE AND USE AS CANCER AND VIRCIDIDE
TWI556741B (en) 2007-08-17 2016-11-11 英特威特國際股份有限公司 Isoxazoline compositions and their use as antiparasitics
US8128968B2 (en) 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
FR2922108A1 (en) 2007-10-11 2009-04-17 Virbac Sa USE OF A 1-N- (HALO-3-PYRIDYLMETHYL) -N-METHYLAMINO-1-ALKYLAMINO -2-NITROETHYLENE DERIVATIVE FOR THE PREPARATION OF A VETERINARY PHARMACEUTICAL COMPOSITION FOR CONTROLLING CHIPS
FR2925337B1 (en) 2007-12-21 2010-01-15 Virbac PHARMACEUTICAL COMPOSITION CONTAINING AN N-PHENYLPYRAZOLE DERIVATIVE AND GLYCOFUROL, USE FOR THE PREPARATION OF A TOPICAL VETERINARY DRUG FOR CONTROLLING CHIPS
US20090317503A1 (en) 2008-06-20 2009-12-24 Ocusoft, Inc. Eyelid Preparation and Method of Use
WO2010005048A1 (en) 2008-07-09 2010-01-14 日産化学工業株式会社 Process for production of isoxazoline-substituted benzoic acid amide compound
RU2011124948A (en) 2008-11-19 2012-12-27 Мериал Лимитед COMPOSITIONS, INCLUDING 1-ARILPIRAZOLE ON YOURSELF OR IN COMBINATION WITH FORMAMIDINE, FOR THE TREATMENT OF PARASITIC INFECTIONS
US9173728B2 (en) 2008-11-19 2015-11-03 Merial Inc. Multi-cavity container having offset indentures for dispensing fluids
AU2008365564B2 (en) 2008-12-16 2015-08-27 Virbac Pharmaceutical composition containing an N-phenylpyrazole derivative, and use thereof for preparing a topical veterinary drug for flea control
BRPI0923009B1 (en) 2008-12-19 2018-07-17 Elanco Tiergesundheit Ag isoxazoline compounds, composition for parasite control and use of isoxazoline compounds for preparation of composition for parasite control
US8313752B2 (en) 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
FR2945797B1 (en) 2009-05-20 2015-11-06 Virbac Sa FOOD, PHARMACEUTICAL OR VETERINARY SAFETY PACKAGING AND METHOD OF MANUFACTURING THE SAME
JP5246182B2 (en) 2010-02-24 2013-07-24 ライオン株式会社 Eye drops, preservatives and preservatives
JP2013521300A (en) 2010-03-03 2013-06-10 ネオキュティス エスアー Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
US10238102B2 (en) 2010-04-12 2019-03-26 Exosect Limited Control of arthropods in animal environments
US8211450B2 (en) 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
CN102260252A (en) 2010-05-24 2011-11-30 盟科医药技术(上海)有限公司 Novel oxazolidinone used for treating bacterial infection
RU2472505C2 (en) 2010-12-07 2013-01-20 Общество с ограниченной ответственностью "Экохимтех" Therapeutic antimalaria drug based on antimalaria agent and probiotic
CA2822839C (en) 2010-12-27 2020-12-29 Intervet International B.V. Topical localized isoxazoline formulation
US20130331768A1 (en) 2010-12-29 2013-12-12 Louis D. Nichamin Eye treatment
CA2826067A1 (en) 2011-02-10 2012-08-16 Novartis Ag Isoxazoline derivatives for controlling invertebrate pests
ES2585555T3 (en) 2011-03-10 2016-10-06 Zoetis Services Llc Spirocyclic derivatives of isoxazoline as antiparasitic agents
EP2694048B1 (en) 2011-04-05 2020-10-07 Optosolve Research & Development Ltd Ophthalmic treatments
PT3172964T (en) 2011-09-12 2020-11-30 Boehringer Ingelheim Animal Health Usa Inc Parasiticidal compositions comprising an isoxazoline active agent, method and uses thereof
CN102552114A (en) 2012-03-19 2012-07-11 段亚东 Metronidazole ophthalmic gel and preparation method and application thereof
US9345522B2 (en) 2012-05-22 2016-05-24 Matthew Songer Bone fixation screw and method
BR112015004135B8 (en) 2012-08-31 2022-11-22 Zoetis Services Llc CRYSTALLINE FORMS OF 1-(5'-(5-(3,5-DICHLORO-4-FLUOROPHENYL)-5-(TRIFLUOROMETHYL)-4,5-DIHYDROISOXAZOL-3-IL)-3'H-SPIRO[AZETIDINE -3,1'-ISOBENZOFURAN]-1-IL)-2-(METHYLSULFONYL)ETHANONE, ITS COMPOSITION, USE AND PREPARATION PROCESS
US9095566B1 (en) 2013-06-28 2015-08-04 Edward Quicksilver Yavitz Eyelash and eyelid margin infections
US9233118B2 (en) 2013-07-08 2016-01-12 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
WO2019126541A1 (en) 2017-12-20 2019-06-27 Attillaps Holdings Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
EP3030084A4 (en) 2013-07-29 2016-07-27 Attillaps Holdings ORGANOPHOSPHATES FOR TREATING SKIN CONDITIONS
ES2971061T3 (en) 2013-12-20 2024-06-03 Intervet Int Bv Isoxazoline compositions and use thereof in the prevention or treatment of parasitic infestations in animals
AU2015267211A1 (en) 2014-05-28 2017-01-12 Lunovus, Llc Ocular eyelid scrub composition for the treatment of Demodex blepharitis
RS63433B1 (en) 2014-06-19 2022-08-31 Attillaps Holdings Acetylcholinesterase inhibitors for treatment of dermatological conditions
TW201625564A (en) 2014-07-23 2016-07-16 陶氏農業科學公司 Molecules having certain pesticidal utilities, intermediates, compositions, and processes, related thereto
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CN106999421A (en) 2014-11-03 2017-08-01 硕腾服务有限责任公司 Agreeable to the taste chewable veterinary composition
BR112017013286A2 (en) 2014-12-22 2018-03-06 Intervet International B.V. isoxazoline compound, and use of an isoxazoline compound.
RU2691412C2 (en) 2015-02-24 2019-06-13 Дзе Боард Оф Трастис Оф Дзе Юниверсити Оф Иллинойс Methods and compositions for treating dry eye disease and other eye diseases
UY36570A (en) 2015-02-26 2016-10-31 Merial Inc INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES OF THE SAME
US20160287566A1 (en) 2015-04-04 2016-10-06 Thomas Lynn Busby Anti-demodectic active agents and topical compositions for the treatment of demodicosis in humans and animals
CN107750159B (en) 2015-06-23 2021-10-29 英特维特国际股份有限公司 Vitamin-containing isoxazoline solution for disinfected drinking water
US20170024748A1 (en) 2015-07-22 2017-01-26 Patient Doctor Technologies, Inc. Guided discussion platform for multiple parties
MX2018002700A (en) 2015-09-10 2018-08-01 Dow Agrosciences Llc Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto.
EP3313413B1 (en) 2015-09-28 2024-12-04 Azura Ophthalmics Ltd Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
UY37137A (en) 2016-02-24 2017-09-29 Merial Inc ANTIPARASITARY COMPOUNDS OF ISOXAZOLINE, INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE THEM, METHODS AND USES OF THE SAME
LT3440062T (en) 2016-04-06 2021-12-10 Boehringer Ingelheim Animal Health USA Inc. PROCEDURE FOR THE MANUFACTURE OF ENANTIOMER-ENRICHED ISOXAXOLINE COMPOUNDS - (S) -AFOXYOLANE CRYSTALLINE TOLUENE SOLVATE
CA3020793C (en) 2016-04-15 2024-05-21 Bayer Animal Health Gmbh Pyrazolopyrimidine derivatives
WO2018081733A1 (en) 2016-10-31 2018-05-03 The California Institute For Biomedical Research Methods and compositions for preventing vector-borne disease transmission
EP3723739B1 (en) 2017-12-15 2024-03-27 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and their use for treating blepharitis
JP7569781B2 (en) 2018-07-27 2024-10-18 アペルタ バイオサイエンシズ，エルエルシー Spinosyn combination for treating Demodex-induced eye and facial abnormalities
DK3846786T3 (en) 2018-09-05 2024-12-02 Zoetis Services Llc Tasty anti-parasitic formulations
US20220160682A1 (en) 2019-04-04 2022-05-26 Tarsus Pharmaceuticals, Inc. Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis
CN114269324A (en) 2019-06-19 2022-04-01 塔苏斯制药有限公司 Isoxazoline anthelmintic formulations and methods for treating blepharitis
US20220249445A1 (en) 2019-06-19 2022-08-11 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
EP4003292A1 (en) 2019-07-22 2022-06-01 Intervet International B.V. Soft chewable veterinary dosage form
WO2021041773A1 (en) 2019-08-28 2021-03-04 Hznp Limited Methods for the treatment of thyroid eye disease
WO2021243014A1 (en) 2020-05-28 2021-12-02 Horizon Therapeutics Ireland Dac Methods for the treatment of idiopathic orbital inflammation and related conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059382A1 (en) * 2001-04-12 2003-03-27 Brandt Loralei Marie Cosmetic compositions containing dispersion polymers
US20080039519A1 (en) * 2004-11-09 2008-02-14 Bayer Healthcare Ag Anti-Demodicosis Agent
US20110059925A1 (en) * 2008-03-26 2011-03-10 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12257263B2 (en) 2014-08-04 2025-03-25 Tarsus Pharmaceuticals, Inc. Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US11690826B2 (en) 2017-12-15 2023-07-04 Tarsus Pharmaceuticals, Inc. Methods for treating demodex blepharitis using lotilaner formulations
US12213964B2 (en) 2017-12-15 2025-02-04 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations
US10835517B2 (en) 2017-12-15 2020-11-17 Tarsus Pharmaceuticals, Inc. Methods for treating ocular demodex using isoxazoline parasiticide formulations
US12171750B2 (en) 2017-12-15 2024-12-24 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US11197847B2 (en) 2017-12-15 2021-12-14 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US11752137B2 (en) 2017-12-15 2023-09-12 Tarsus Pharmaceuticals, Inc. Ophthalmic compositions for treating ocular Demodex using lotilaner formulations
US11690827B2 (en) 2017-12-15 2023-07-04 Tarsus Pharmaceuticals, Inc. Methods for treating ocular Demodex using lotilaner formulations
CN112770742A (en) * 2018-07-27 2021-05-07 阿佩塔生物科学有限公司 Spinosad formulations for the treatment of demodex-induced eye and face diseases
CN113242747A (en) * 2018-10-12 2021-08-10 好利安科技有限公司 Macrolide formulations, method for preparing them and use of said formulations in the treatment of diseases secondary to ocular parasites
AU2020333005B2 (en) * 2019-08-20 2022-03-24 Vishwanath PADMANABHAN Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
US12161752B2 (en) * 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
US20210052490A1 (en) * 2019-08-20 2021-02-25 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
WO2021033154A1 (en) * 2019-08-20 2021-02-25 Padmanabhan Vishwanath Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis

Also Published As

Publication number Publication date
US12257263B2 (en) 2025-03-25
US20200338105A1 (en) 2020-10-29
US20220125817A1 (en) 2022-04-28
WO2016022066A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
US12257263B2 (en) Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US8128968B2 (en) Compositions and methods for treating Demodex infestations
Holzchuh et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin
US8440240B2 (en) Method for treating ocular demodex
Ávila et al. Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.: a randomized clinical trial
Sandford et al. Therapeutic potential of castor oil in managing blepharitis, meibomian gland dysfunction and dry eye
JP2009184951A (en) External skin care preparation composition
JP2024016022A (en) Cannabinoid dosing regimen for dermatitis and inflammatory skin conditions
WO2012095719A1 (en) Melatonin and an antimicrobial or antibacterial agent for the treatment of acne
US20240033230A1 (en) Compositions for the treatment of blepharitis
US20160287566A1 (en) Anti-demodectic active agents and topical compositions for the treatment of demodicosis in humans and animals
AU2024205420A1 (en) Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
PL223972B1 (en) Essential oil and aloe vera for the treatment and prophylaxis of inflammation caused by grain mites, especially blepharitis, a pharmaceutical composition comprising an essential oil and/or aloe, and the use of the essential oil and aloe vera and its composition for the preparation for the treatment and prevention of these inflammatory conditions
US20100003354A1 (en) Linseed Extract Medicament for Application to the Eye
US20220071924A1 (en) Treatment of ocular diseases with ophthalmic tapinarof compositions
ES2850366T3 (en) Composition for the treatment of blepharitis containing terpinen-4-ol
RU2816363C2 (en) Eye disease treatment
US20240189377A1 (en) Methods of using compositions comprising an iceland moss extract
EP4486329A1 (en) Topical formulation to decrease skin inflammation or redness
CN117582442A (en) Application of dipyridamole in preparation of product for preventing and treating mosquito bites
US20220249446A1 (en) Composition Comprising at Least One Oxazoline for Inhibiting the Growth of Malassezia Yeasts Involved in Cradle Cap, in Particular
US20180092870A1 (en) Butyrate Based Skin Formulation
PL225087B1 (en) Lavandin oil and aloe to be used in therapy and preventive treatment of inflammatory conditions caused by Demodex mites, preferably inflammations of eyelid margins, pharmaceutical composition containing lavandin oil and/or aloe and application of lavandin oil and aloe and composition thereof for the production of the preparation to be used in therapy and preventive treatment of the above mentioned inflammatory conditions
PL225086B1 (en) Eucalyptus oil and aloe to be used in therapy and preventive treatment of inflammatory conditions caused by Demodex mites, preferably inflammations of eyelid margins, pharmaceutical composition containing eucalyptus oil and/or aloe and application of eucalyptus oil and aloe and composition thereof for the production of the preparation to be used in therapy and preventive treatment of the above mentioned inflammatory conditions

Legal Events

Date Code Title Description
AS Assignment

Owner name: JERRY TAN EYE SURGERY PTE LTD, SINGAPORE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAN, TIANG HIN JERRY;POR, YONG MING;REEL/FRAME:041668/0880

Effective date: 20170317

Owner name: TARSUS PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JERRY TAN EYE SURGERY PTE LTD;REEL/FRAME:041668/0935

Effective date: 20170317

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION